Electrocardiographic changes with ziprasidone [1]

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 6, 2006, Pages 636-637

  Loebel, Antony ^a   Miceli, Jeffrey ^a   Chappell, Phillip ^a   Siu, Cynthia ^b,c  

^a PFIZER INC   (United States)

^b Data Power DP Inc   (United States)

^c PFIZER

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART RATE; HUMAN; LETTER; MAXIMUM ALLOWABLE CONCENTRATION; METHODOLOGY; PEDIATRICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RR INTERVAL;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DATA INTERPRETATION, STATISTICAL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; RESEARCH DESIGN; SELECTION BIAS; THIAZOLES; TOURETTE SYNDROME;

EID: 33744781783     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000215151.53776.5a     Document Type: Letter

References (7)

1. Blair J, Scahill L, State M, Martin A (2005), Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73-79
2. DelBello M, Ice K, Fisher DO, Versavel M, Miceli JJ (2005), Ziprasidone in the treatment of children and adolescents with bipolar mania or schizophrenia: an open-label, dose-ranging safety and tolerability study. Poster presented at New Clinical Drug Evaluation Unit, 45th Annual Meeting, Boca Raton, FL, June 6-9
3. Fenichel RR, Malik M, Antzelevitch C et al. (2004), Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495
4. International Conference on Harmonization (ICH) E14 (2005). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, http://www.fda.gov/cder/guidance/guidance.htm. Accessed August 10, 2004
5. Labellarte MJ, Crosson JE, Riddle MA (2003), The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:642-650
6. Malik M (2001), Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411-420
7. Malik M (2003), Drug-induced QT interval prolongation - why is it of concern? Presented at the FDA Anesthetic and Life Support Drugs Advisory Committee Meeting; Gaithersburg, MD, November 18;http://www.fda.gov/ohrms/ dockets/ac/03/slides/4000S1_05_Malik_files/frame.htm. Accessed October 5, 2005